ChiCTR2600126495 版本V1.0 版本创建时间2026/06/10 09:05:56 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600126495 

最近更新日期:

Date of Last Refreshed on:

2026-06-10 09:05:49 

注册时间:

Date of Registration:

2026-06-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

经皮穴位电刺激预防术后谵妄的时效研究

Public title:

A time?effect study of transcutaneous electrical acupoint stimulation for the prevention of postoperative delirium

注册题目简写:

English Acronym:

研究课题的正式科学名称:

经皮穴位电刺激预防术后谵妄的时效研究

Scientific title:

A time?effect study of transcutaneous electrical acupoint stimulation for the prevention of postoperative delirium

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

熊秋菊 

研究负责人:

黎平 

Applicant:

Xiong Qiuju 

Study leader:

Li Ping 

申请注册联系人电话:

Applicant telephone:

+86 182 2506 2100

研究负责人电话:

Study leader's
telephone:

+86 130 6233 7738

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xiongqiuju2003@163.com

研究负责人电子邮件:

Study leader's E-mail:

202626@hospital.cqmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

重庆市 渝中区 其他

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国重庆市渝中区友谊路1号 No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing

研究负责人通讯地址:

中国重庆市渝中区友谊路1号 No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing

Applicant address:

No. 1, Yifeng Road, Yuzhong District, Chongqing, China

Study leader's address:

No. 1, Yifeng Road, Yuzhong District, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

610041

研究负责人邮政编码:

Study leader's postcode:

610041

申请人所在单位:

重庆医科大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Chongqing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2026年科研论审(ZZ2026-0311-01)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属第一医院伦理委员会

Name of the ethic committee:

The Ethics Committee of the First Hospital of Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-04-27 00:00:00

伦理委员会联系人:

李俊龙

Contact Name of the ethic committee:

Lijun Long

伦理委员会联系地址:

中国重庆市渝中区友谊路1号

Contact Address of the ethic committee:

No. 1, Yifeng Road, Yuzhong District, Chongqing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 23 8901 2558

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆医科大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

中国重庆市渝中区友谊路1号

Primary sponsor's address:

No. 1, Yifeng Road, Yuzhong District, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第一医院

具体地址:

中国重庆市渝中区友谊路1号

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Address:

No. 1, Yifeng Road, Yuzhong District, Chongqing, China

经费或物资来源:

重庆市卫生健康委物理医学与精准康复重点实验室

Source(s) of funding:

Chongqing Municipal Health Commission Key Laboratory of Physical Medicine and Precision Rehabilitation

研究疾病:

术后谵妄  

Target disease:

Postoperative Delirium, POD

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评估术前及术中经皮穴位电刺激对骨科老年患者术后谵妄的预防效应  

Objectives of Study:

To evaluate the preventive effect of preoperative and intraoperative transcutaneous electrical acupoint stimulation on postoperative delirium in elderly orthopedic patients

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)拟全身麻醉下行骨科髋膝关节置换术的患者; 2)年龄>=65 岁; 3)自愿签署知情同意书。

Inclusion criteria

1) Patients scheduled to undergo elective hip or knee arthroplasty under general anesthesia; 2) Age >=65 years; 3)Voluntary informed consent signed

排除标准:

1)经皮电刺激禁忌者,包括局部皮肤破损、感染或体内有植入电生理装置者; 2)交流障碍、无法配合研究者,如精神疾病等; 3)伴有危及生命的情况或生命体征不稳定者; 4)干预前有痴呆、谵妄症状或认知障碍; 5)药物滥用或依赖; 6)在入选研究前的 3 个月内参与了其他临床试验者; 7)研究者认为不宜纳入的其他情况

Exclusion criteria:

1) Contraindications to transcutaneous electrical stimulation, including local skin damage, infection, or presence of an implanted electrophysiological device; 2) Communication disorders or inability to cooperate with the investigator (e.g., due to psychiatric illness); 3) Life?threatening conditions or unstable vital signs; 4) Preexisting dementia, delirium symptoms, or cognitive impairment before intervention; 5) Substance abuse or dependence; 6) Participation in another clinical trial within 3 months prior to enrollment in this study; 7) Other conditions deemed unsuitable for inclusion by the investigator.

研究实施时间:

Study execute time:

From 2026-06-10 00:00:00 To 2027-10-20 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-10 00:00:00 To 2027-10-20 00:00:00

干预措施:

Interventions:

组别:

TEAS组

样本量:

132

Group:

TEAS group

Sample size:

干预措施:

试验组在术前 2 天,每日TEAS 内关穴、神门穴、足三里、太冲穴,每天 2 次,每次持续 30min,以及手术当日麻醉前30min 至手术结束期间给予 TEAS

干预措施代码:

Intervention:

In the experimental group, TEAS was applied to the Neiguan (PC6), Shenmen (HT7), Zusanli (ST36), and Taichong (LR3) acupoints starting 2 days before surgery, twice daily, with each session lasting 30 minutes. Additionally, TEAS was administered from 30 minutes before anesthesia induction until the end of surgery on the day of the procedure.

Intervention code:

组别:

对照组

样本量:

132

Group:

Control group

Sample size:

干预措施:

对照组予以假针刺处理,即电极片贴敷于相同穴位,连接刺激仪,但不给予电流刺激

干预措施代码:

Intervention:

In the control group, sham TEAS was applied, in which electrode pads were placed on the same acupoints and connected to the stimulator, but no electrical current was delivered.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Level of the institution:

Tertiary, Tertiary A

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆市九龙坡区中医院 

单位级别:

三级甲等 

Institution
hospital:

Chongqing Jiulongpo District Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary, Tertiary A

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆大学附属三峡医院 

单位级别:

三级甲等 

Institution
hospital:

Chongqing University Three Gorges Hospital

Level of the institution:

Tertiary, Tertiary A

测量指标:

Outcomes:

指标中文名:

POD 发生率

指标类型:

主要指标

Outcome:

POD incidence

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

每日疼痛评分

指标类型:

次要指标

Outcome:

Daily pain score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后镇静镇痛药用量

指标类型:

次要指标

Outcome:

Postoperative sedative and analgesic consumption

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

睡眠质量评分

指标类型:

次要指标

Outcome:

Sleep quality score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

首次喝水时间

指标类型:

次要指标

Outcome:

Time to first oral water intake

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

首次进食时间

指标类型:

次要指标

Outcome:

Time to first oral food intake

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

首次下床活动时间

指标类型:

次要指标

Outcome:

Time to first ambulation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症

指标类型:

次要指标

Outcome:

Postoperative complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

炎性指标

指标类型:

次要指标

Outcome:

Inflammatory markers

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由不参与本临床试验的独立统计学家,使用统计软件 PASS 15.0 生成一份随机分配序列,区组随机号长度为 4 位。以 1:1 的比例将受试者分配至试验组或对照组。序列生成后,将被打印并严格保密,并根据上述随机序列,制备按顺序编号的、不透明的信封,每个信封外标注唯一序号(从 0001 开始),信封内包含对应的分组分配信息。

Randomization Procedure (please state who generates the random number sequence and by what method):

An independent statistician not involved in this clinical trial generated a randomization sequence using PASS 15.0 software, with a block length of 4. Eligible participants were assigned to either the experimental group or the control group in a 1:1 ratio. After generation, the sequence was printed and kept strictly confidential. Based on the randomization sequence, sequentially numbered, opaque envelopes were prepared, each labeled with a unique number (starting from 0001). The corresponding group allocation information was placed inside each envelope.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

N/A

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表由CRF表记录并实施管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case report forms (CRFs) will be used to record and manage the data.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-06-10 09:05:49